Aprea Therapeutics gets FDA breakthrough therapy status for APR-246 in MDS

This article was originally published here

The APR-246, azacitidine combination has been granted breakthrough therapy status for the treatment of myelodysplastic syndromes in patients having a susceptible TP53 mutation. Myelodysplastic syndromes are defined as

The post Aprea Therapeutics gets FDA breakthrough therapy status for APR-246 in MDS appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply